(Q33978551)

30 July 2017

1 reference

title

Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity (English)

1 reference

30 July 2017

5

Chaejoon Cheong

1 reference

30 July 2017

Ravichandran N Murugan

1

1 reference

30 July 2017

Jung-Eun Park

2

1 reference

30 July 2017

Eun-Hee Kim

3

1 reference

30 July 2017

Song Yub Shin

4

1 reference

30 July 2017

Kyung S Lee

6

1 reference

30 July 2017

Jeong Kyu Bang

7

1 reference

30 July 2017

language of work or name

1 reference

29 July 2011

1 reference

30 July 2017

1 reference

30 July 2017

32

1 reference

30 July 2017

3

1 reference

30 July 2017

209-220

1 reference

https://scigraph.springernature.com/pub.10.1007/s10059-011-0126-3

30 July 2017

0 references

cites work

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo-box domain: a versatile mediator of polo-like kinase function

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo-like kinases: conservation and divergence in their functions and regulation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Structure of theBrachydanio rerioPolo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

A quantitative analysis of kinase inhibitor selectivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Selectivity-determining residues in Plk1

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Structure of the catalytic domain of human polo-like kinase 1

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Probing cell-division phenotype space and Polo-like kinase function using small molecules

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Rational design of inhibitors that bind to inactive kinase conformations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo-like kinases: a team in control of the division

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Normal cells, but not cancer cells, survive severe Plk1 depletion

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

On the road to cancer: aneuploidy and the mitotic checkpoint

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Progress in the discovery of polo-like kinase inhibitors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo-like kinases (Plks) and cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo-like kinases and oncogenesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo-like kinases and the orchestration of cell division

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

The Sak polo-box comprises a structural domain sufficient for mitotic subcellular localization

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

Polo-like kinase, a novel marker for cellular proliferation.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887635

A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10059-011-0126-3

Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10059-011-0126-3

Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10059-011-0126-3

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10059-011-0126-3

Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10059-011-0126-3

The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10059-011-0126-3

Targeting polo-like kinase 1 for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10059-011-0126-3

Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease

21 January 2018

1 reference

12 December 2020

The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1

1 reference

12 December 2020

Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck

1 reference

12 December 2020

PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas

1 reference

12 December 2020

Tumor regression by combination antisense therapy against Plk1 and Bcl-2

1 reference

12 December 2020

10.1007/S10059-011-0126-3

Identifiers

DOI

1 reference

30 July 2017

1 reference

30 July 2017

1 reference